drugset / Trial / NCT00787852
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Terminated
11 enrolled
Brown University
Memorial Hospital of Rhode Island · collabRhode Island Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and potentially resectable disease.
Timeline
- Start
- 2009-03
- Primary completion
- 2011-03
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 50 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 70 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | — |
| Background | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 50 mg/m2 | Intravenous |